Limits...
Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer.

Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, Zhou W, Wu W, Li Q - Diagn Pathol (2012)

Bottom Line: Thus, the aim of this study was to investigate the diagnostic and prognostic values of miR-100 in this disease.Moreover, low miR-100 expression clearly predicted poorer PFS (P = 0.001) and OS (P < 0.001).In the multivariate analysis, low miR-100 expression was an independent prognostic factor for both PFS (P = 0.01) and OS (P = 0.008).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, the First Affiliated Hospital, Bengbu Medical College, Bengbu 233030, People's Republic of China. wangshenganhui@126.com

ABSTRACT

Objective: MicroRNA-100 (miR-100) has been demonstrated to be downregulated in bladder cancer tissues, and enforced expression of this miRNA may inhibit cell growth and colony formation of human bladder cancer 5637 cells in vitro. However, the clinical significance of miR-100 in human bladder cancer has not yet been elucidated. Thus, the aim of this study was to investigate the diagnostic and prognostic values of miR-100 in this disease.

Methods: Expression levels of miR-100 in 126 pairs of bladder cancer and adjacent normal tissues were detected by TaqMan real-time quantitative RT-PCR assay. In order to determine its prognostic value, overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis.

Results: Expression levels of miR-100 in bladder cancer tissues were significantly lower than those in adjacent normal tissues (mean expression level: 2.6 ± 1.2 vs. 3.9 ± 1.5, P < 0.001). When categorized into low vs. high expression, low miR-100 expression was negatively associated with the stage (P = 0.01), the recurrence (P = 0.008), the progression (P = 0.01), and the death (P < 0.001) of patients with bladder cancer. Moreover, low miR-100 expression clearly predicted poorer PFS (P = 0.001) and OS (P < 0.001). In the multivariate analysis, low miR-100 expression was an independent prognostic factor for both PFS (P = 0.01) and OS (P = 0.008).

Conclusion: Our data offer the convincing evidence that miR-100 may play an important role in the progression of bladder cancer and that the reduced expression of this miRNA may be independently associated with shorter PFS and OS of patients, suggesting that miR-100 might be a potential marker for further risk stratification in the treatment of this cancer.

Virtual slides: The virtual slides' for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1105483419841671.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier survival curves for bladder cancer patients according to the expression of miR-100. (A) Progression-free survival (PFS); (B) overall survival (OS).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3539897&req=5

Figure 2: Kaplan-Meier survival curves for bladder cancer patients according to the expression of miR-100. (A) Progression-free survival (PFS); (B) overall survival (OS).

Mentions: To investigate OS or PFS, we defined a time point of 36 months. During the time study, 26 (20.6%) patients presented a progression and 100 (79.4%) did not. In patients who progressed, 20 (76.9%) had low miR-100 expression. The 3-year OS rates of patients who were low (n = 78) and high (n = 48) for miR-100 expression were 29.5% and 68.8%, respectively (Table3). In univariate analysis, low miR-100 expression (P < 0.001), the stage (P = 0.006), the grade (P = 0.02), and CIS (P = 0.01) were significant predictors of short OS (Table3). For the 3-year PFS rates, patients with low miR-100 expression represented 20.5% and patients without, 54.2% (Table3). Low miR-100 expression (P = 0.001), stage (P = 0.008), grade (P = 0.03), and CIS (P = 0.02) were also negative predictors of the PFS (Table3). Figure2 shows the OS and PFS curves with respect of miR-100 expression. More importantly, the prognostic value of miR-100 in bladder cancer patients was higher than that of tumor stage (P value for OS: <0.001 vs. 0.006; for PFS: 0.001 vs. 0.008; Table3), grade (P value for OS: <0.001 vs. 0.03; for PFS: 0.001 vs. 0.02; Table3) and CIS (P value for OS: <0.001 vs. 0.02; for PFS: 0.001 vs. 0.01; Table3).


Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer.

Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, Zhou W, Wu W, Li Q - Diagn Pathol (2012)

Kaplan-Meier survival curves for bladder cancer patients according to the expression of miR-100. (A) Progression-free survival (PFS); (B) overall survival (OS).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3539897&req=5

Figure 2: Kaplan-Meier survival curves for bladder cancer patients according to the expression of miR-100. (A) Progression-free survival (PFS); (B) overall survival (OS).
Mentions: To investigate OS or PFS, we defined a time point of 36 months. During the time study, 26 (20.6%) patients presented a progression and 100 (79.4%) did not. In patients who progressed, 20 (76.9%) had low miR-100 expression. The 3-year OS rates of patients who were low (n = 78) and high (n = 48) for miR-100 expression were 29.5% and 68.8%, respectively (Table3). In univariate analysis, low miR-100 expression (P < 0.001), the stage (P = 0.006), the grade (P = 0.02), and CIS (P = 0.01) were significant predictors of short OS (Table3). For the 3-year PFS rates, patients with low miR-100 expression represented 20.5% and patients without, 54.2% (Table3). Low miR-100 expression (P = 0.001), stage (P = 0.008), grade (P = 0.03), and CIS (P = 0.02) were also negative predictors of the PFS (Table3). Figure2 shows the OS and PFS curves with respect of miR-100 expression. More importantly, the prognostic value of miR-100 in bladder cancer patients was higher than that of tumor stage (P value for OS: <0.001 vs. 0.006; for PFS: 0.001 vs. 0.008; Table3), grade (P value for OS: <0.001 vs. 0.03; for PFS: 0.001 vs. 0.02; Table3) and CIS (P value for OS: <0.001 vs. 0.02; for PFS: 0.001 vs. 0.01; Table3).

Bottom Line: Thus, the aim of this study was to investigate the diagnostic and prognostic values of miR-100 in this disease.Moreover, low miR-100 expression clearly predicted poorer PFS (P = 0.001) and OS (P < 0.001).In the multivariate analysis, low miR-100 expression was an independent prognostic factor for both PFS (P = 0.01) and OS (P = 0.008).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, the First Affiliated Hospital, Bengbu Medical College, Bengbu 233030, People's Republic of China. wangshenganhui@126.com

ABSTRACT

Objective: MicroRNA-100 (miR-100) has been demonstrated to be downregulated in bladder cancer tissues, and enforced expression of this miRNA may inhibit cell growth and colony formation of human bladder cancer 5637 cells in vitro. However, the clinical significance of miR-100 in human bladder cancer has not yet been elucidated. Thus, the aim of this study was to investigate the diagnostic and prognostic values of miR-100 in this disease.

Methods: Expression levels of miR-100 in 126 pairs of bladder cancer and adjacent normal tissues were detected by TaqMan real-time quantitative RT-PCR assay. In order to determine its prognostic value, overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox proportional hazard analysis.

Results: Expression levels of miR-100 in bladder cancer tissues were significantly lower than those in adjacent normal tissues (mean expression level: 2.6 ± 1.2 vs. 3.9 ± 1.5, P < 0.001). When categorized into low vs. high expression, low miR-100 expression was negatively associated with the stage (P = 0.01), the recurrence (P = 0.008), the progression (P = 0.01), and the death (P < 0.001) of patients with bladder cancer. Moreover, low miR-100 expression clearly predicted poorer PFS (P = 0.001) and OS (P < 0.001). In the multivariate analysis, low miR-100 expression was an independent prognostic factor for both PFS (P = 0.01) and OS (P = 0.008).

Conclusion: Our data offer the convincing evidence that miR-100 may play an important role in the progression of bladder cancer and that the reduced expression of this miRNA may be independently associated with shorter PFS and OS of patients, suggesting that miR-100 might be a potential marker for further risk stratification in the treatment of this cancer.

Virtual slides: The virtual slides' for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1105483419841671.

Show MeSH
Related in: MedlinePlus